TMCnet News

AIBODY Partners with German Heart Centre Berlin to Revolutionize Diagnosis and Treatment of Congenital Heart Disease
[August 04, 2022]

AIBODY Partners with German Heart Centre Berlin to Revolutionize Diagnosis and Treatment of Congenital Heart Disease

AIBODY, the world's first Physiology-as-a-Service platform, announced today that it has signed a collaboration agreement with the German Heart Centre Berlin (DHZB), a leading medical research institute specializing in cardiovascular disease. This agreement focuses on the development of a suite of innovative solutions that will facilitate the diagnosis and treatment of congenital heart disease.

The collaboration will utilize AIBODY's digital human physiology engine to create a lifelike, highly detailed 3D and 4D model of a beating human heart, capable of replicating the broad range of cardiovascular pathologies found in patients with congenital heart defects. Informed by clinical data shared by the DHZB cardiology team, the model will become a dynamic learning resource for practicing and trainee clinicians worldwide, including cardiologists, pediatricians and radiologists, expanding their working knowledge of congenital heart defects and helping them more effectively recognize such conditions in actual patients.

Once the educational resource is complete, AIBODY will proceed to develop AI tools that will automatically extract features from cardiac sonograms to create an anatomically accurate, "digitally twinnd" 3D and 4D model of a patient's heart, providing a diagnostic aid to doctors and radiologists to help optimize personalized diagnosis and treatment for each patient.

"We will begin by creating a comprehensive catalogue of conditions to provide a 'living' reference guide for doctors and radiologists to help recognize and define what they are seeing on patient imagery," said Richard Littlehales, CEO of AIBODY. "Our ultimate goal is to build an AI-driven diagnostic device based on creating a 'digital twin' of each individual patient's heart, reflecting their actual physiology and giving the clinical teams a better understanding of that patient's specific condition and its likely development over time."

"By combining our clinical knowledge and experience with the cutting-edge simulation technology AIBODY is bringing to the table, we will enhance our capacity to diagnose and treat patients, leading to better outcomes for patients around the world," said Prof. Stanislav Ovroutski, senior consultant of the DHZB Clinic for Congenital Heart Defects and Pediatric Cardiology. "Our first product will be a dynamic clinical reference guide that doctors will be able to access on their phones or tablets. We expect to have that ready within a year."


AIBODY is a cloud-based Physiology-as-a-Service platform that offers real-time, immersive medical simulations using the world's first digital human organism. AIBODY's unique approach produces highly detailed, lifelike physiological responses to virtually any simulated medical condition or treatment protocol, recreating interrelated biophysical, physiological, and biochemical processes occurring within a human body. AIBODY has been spun off from AUG Global, the international technology group, and raised a seed funding round from leading global venture capital firms. For further information, please visit

About German Heart Centre Berlin

The German Heart Centre Berlin (Deutsches Herzzentrum Berlin) is an internationally renowned high-performance hospital and medical research center specializing in the treatment of cardiovascular and thoracic diseases, implantation of mechanical circulatory support systems, and heart and lung transplantation. For further information, please visit

[ Back To's Homepage ]